TRENDING :  Market Movers  |  Top 50   AMD (0%)    NFLX (0%)    SPY (0%)    SPX (0%)    DGAZ (0%)    TSLA (0%)    UGAZ (0%)    VXXB (0%)    VXX (0%)    TWLO (0%)    TLT (0%)    SQQQ (0%)    BOIL (0%)    BABA (0%)    SM (0%)    PCG (0%)    NBEV (0%)    MNGA (0%)    MBOT (0%)    INPX (0%)

 CATB - Catabasis Pharmaceuticals

$6.69 (0%)

Next Earnings



Analyst Rating

Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High NaN
Low NaN
Average NaN
Current $6.69

No recommendations found.
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Catabasis Pharmaceuticals Inc CATB has been struggling lately but the selling pressure may be coming to an end soon That is because CATB recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern A hammer chart pattern is

Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks but investors should always be looking for companies that are outperforming their peers Is Catabasis Pharmaceuticals CATB one of those stocks right now By taking a look at the stock s year to date performance in comparison to its Medical peers

Agenus (AGEN) Surges: Stock Moves 9.4% Higher

Agenus Inc AGEN was a big mover last session as the company saw its shares rise more than 9 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the

BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG

BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG

Why Canada Goose Holdings, Catabasis Pharmaceuticals, and Globalstar Jumped Today

2018 ended on a quiet note Monday as stock market benchmarks posted modest advances on the last day of the year Overall 2018 was disappointing for most investors with the Dow Jones Industrial Average S amp P 500 and Nasdaq Composite all finishing well below where